Aurinia Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Aurinia Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Aurinia Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Aurinia Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals) is a biopharmaceutical company focused on developing therapies for autoimmune diseases. Its pipeline product includes voclosporin (lupkynis) an orally administered CNI immunosuppressant, to treat adult patients with active lupus nephritis. The company also develops Aritinercept, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It collaborates with Otsuka Pharmaceutical Co., Ltd for the development and commercialization of oral voclosporin. The company operates in Canada and the US. Aurinia Pharmaceuticals is headquartered in Edmonton, Alberta, Canada.
Headquarters
Canada
Address
#140, 14315 - 118 Avenue, Edmonton, Alberta, T5L4S6
Website
www.auriniapharma.com
Telephone
1 250 7442487
No of Employees
128
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AUPH (NASD)
Revenue (2024)
$283.1M
20.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
4893.1%
(2024 vs 2023)
Market Cap*
$2.1B
Net Profit Margin (2024)
XYZ
4,041.6%
(2024 vs 2023)
* As of and is in US$
Aurinia Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Lupkynis |
| LUPKYNIS (Voclosporin): Lupus Nephritis | |
| Aritinercept: Autoimmune Diseases |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In September, the company received approval from the Japanese Ministry of Health, Labour, and Welfare for voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil to treat lupus nephritis. |
| 2023 | Plans/Strategy | In June, the company announced its plans to consider a wide range of options for the company including a potential sale, merger, or other strategic transaction. |
| 2023 | Regulatory Approval | In May, the company announced that Swissmedic approved marketing authorization of LUPKYNIS (voclosporin) for the development and commercialization of voclosporin for the treatment of lupus nephritis (LN). |
Competitor Comparison
| Key Parameters | Aurinia Pharmaceuticals Inc | Chinook Therapeutics Inc | AffinityImmuno Inc | Borealis Biosciences Inc | Edesa Biotech Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | Canada | Canada | Canada |
| City | Edmonton | Seattle | Charlottetown | Vancouver | Markham |
| State/Province | Alberta | Washington | Prince Edward Island | British Columbia | Ontario |
| No. of Employees | 128 | 214 | - | - | 17 |
| Entity Type | Public | Private | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kevin Tang | Chief Executive Officer; Chairman | Executive Board | 2026 | 59 |
| Michael Hearne | Chief Financial Officer | Senior Management | 2026 | 63 |
| Ryan Cole | Chief Operating Officer | Senior Management | 2026 | 39 |
| Stephen Robertson | Chief Compliance Officer; Chief Legal Officer; Secretary | Senior Management | 2026 | 44 |
| Thomas Wei | Chief Scientific Officer | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer